23 results about "Rat liver" patented technology

The invention relates to the field of biomedical application of inorganic materials, in particular to application of lanthanum carbonate in preparation of drugs for resisting liver cirrhosis and inhibiting liver inflammations, the drugs comprise lanthanum carbonate and pharmaceutically acceptable auxiliary materials, the drugs are ground and then mixed with food to prepare a drug mixture, and the drug mixture is prepared into the drug for resisting liver cirrhosis and inhibiting liver inflammations. The mass ratio of the lanthanum carbonate in the medicine mixture is 1-10%, and the mechanism of the lanthanum carbonate for treating the liver cirrhosis is as follows: interference or blocking of activation and proliferation of hepatic stellate cells, inhibition of extracellular matrix generation and promotion of extracellular matrix degradation. According to the invention, a rat liver cirrhosis model is constructed through chemical induction, and the effects of reversing liver cirrhosis and inhibiting liver inflammation are found when a rat is treated by taking lanthanum carbonate orally, so that a new candidate drug is provided for clinical treatment of liver cirrhosis.

The invention belongs to the technical field of biological medicine, and particularly relates to application of hUC-MSCs combined with Met in preparation of anti-diabetic drugs. The diabetes mellitus is particularly type 2 diabetes mellitus. Through construction of a T2DM rat model, paraffin tissue section detection, serum ELISA, cell experiments and the like, researches prove that T2DM can be effectively treated by HUC-MSCs combined with Met treatment, including reduction of body blood sugar and recovery of blood sugar regulation ability; liver injury caused by T2DM is relieved and repaired; the glycolipid metabolism of the liver of the T2DM rat is improved; the immune inflammation disorder caused by T2DM is relieved; and the apoptosis level of liver cells is improved. And compared with a single hUC-MSCs or Met treatment mode, the combined treatment mode has a better treatment effect. The invention provides a theoretical basis and a new treatment strategy for treatment of T2DM.

The invention discloses a method for constructing a polycystic ovarian syndrome (PCOS) rat model with reduced sex hormone binding globulin (SHBG) on the basis of ruminococcus aureus with the preservation number of ATCC29149, and belongs to the technical field of animal models. According to the present invention, the bacterial strain is subjected to anaerobic culture to prepare the bacterial liquid, the dosage is 0.2-1 mL / 100 g, the intragastric administration frequency is one time per day to two times per week, and the time lasts for 4-8 weeks, such that the SHBG synthesis of the rat liver is induced to decrease, and the PCOS pathological characteristics such as testosterone level increase, estrus cycle disorder, ovarian polycystic change, insulin resistance and the like are initiated; the problem that a traditional hormone induction method does not conform to the physiological status is solved, the modeling period of a high-fat diet induction method is shortened, and an efficient experimental tool is provided for PCOS mechanism research and drug development.

The utility model discloses a hepatocyte separation device for a hepatocyte damage model rat, and relates to the technical field of centrifugal devices. The device comprises a shell, an inlet and outlet is formed in the middle of the top face of the shell, a centrifugal control assembly is arranged in the shell, an electric push rod is fixedly installed on the surface of the centrifugal control assembly, and the telescopic end of the electric push rod is movably sleeved with a supporting frame; the surface of the supporting frame is provided with a test tube placing assembly used for storing hepatocyte sample test tubes, the surface of the telescopic end of the electric push rod is provided with a positioning assembly used for limiting the supporting frame, the centrifugal control assembly comprises a motor, and the motor is fixedly installed at the bottom of the inner wall of the shell. During use, the effect of conveniently taking and placing centrifugal hepatocyte sample test tubes is achieved, the situation that the test tubes collide with the device in the test tube moving process is avoided, and the centrifugal work is more convenient.

The present invention provides a large Stokes shift near-infrared fluorescent probe for detecting HClO, its preparation method and biological imaging application, belonging to the field of bioanalysis technology. Based on the strategy of modifying the substituents at the 3,6 positions of xanthene, the present invention constructs a large Stokes shift near-infrared fluorescent probe for specifically recognizing HClO. Optical experiments show that the emission wavelength of the probe for detecting HClO is 776 nm, the Stokes shift reaches 148 nm, with strong selectivity, high sensitivity, and a detection limit as low as 4.95 nM, which can greatly reduce the interference of background fluorescence in biological imaging applications. The fluorescent probe of the present invention has almost no cytotoxicity and can be applied to the detection and imaging of HClO in living cells MCF-7 and rat liver tissues, with a tissue penetration depth of 140 μm.

The antioxidant activity of alpha-tocopherol polyethylene glycol 1000 succinate (TPGS) and of alpha-tocopherol succinate (TS) has been examined in isolated hepatocytes and microsomal fractions from rat liver. Both TPGS and TS require esterase activity to yield free alpha-tocopherol and, hence, antioxidant activity. TPGS and TS consistently exerted a more effective antioxidant protection than an equivalent amount of directly-added free alpha-tocopherol. The low antioxidant efficiency of directly added free alpha-tocopherol in such water-based experimental systems as used here seems to be due to its extreme hydrophobicity. TPGS, on the other hand, is an extremely hydrophilic compound which is being examined as a useful source of alpha-tocopherol in certain clinical situations and is here shown to be a convenient and effective source for experimental studies into lipid peroxidation and antioxidant mechanisms.

The invention provides a pharmaceutical composition for treating liver injury and hepatic fibrosis, and relates to the technical field of biological medicines. The pharmaceutical composition is prepared from a peucedanum decursum extract, a penthorum chinense pursh extract, a spanishneedles herb extract and a nux prinsepiae extract. The pharmaceutical composition shows an excellent protective effect on a carbon tetrachloride induced hepatocyte injury model. The pharmaceutical composition disclosed by the invention has obvious treatment and protection effects on carbon tetrachloride induced rat hepatic fibrosis, and the anti-hepatic fibrosis effect is realized by improving four indexes of liver function and hepatic fibrosis, reducing the level of inflammatory factors in the liver and relieving inflammatory reaction in the hepatic fibrosis process. The pharmaceutical composition disclosed by the invention is expected to be further developed and popularized as a medicine for treating liver injury and hepatic fibrosis.

The invention discloses a method for establishing a shock rat model with liver-spleen combined injury, which is characterized in that: on the basis of injury operation on the liver and spleen of a rat, when the liver and spleen of the rat are simultaneously injured, a blood loss intervention experiment is performed on the rat, so that the establishment of the shock rat model with liver-spleen combined injury is realized; the blood loss mode of the rat better conforms to the clinical blood loss condition, and the pathological process of the blood loss shock caused by the rat liver-spleen combined injury can accurately simulate the pathological process of the blood loss shock caused by the human body liver-spleen combined injury and is closer to the clinical practice; the device has the advantages that the treatment effect of a liver-spleen combined injury patient after blood substitutes are infused can be accurately simulated, and measures for coping with serious shock caused by liver-spleen combined injury can be conveniently and comprehensively studied.

The invention belongs to the technical field of biological medicine, and provides dimethyl fumarate and application of a signal channel thereof in inhibition of arsenic-induced rat liver and kidney immune inflammation reaction. According to the present invention, with the application of the sodium arsenite in the rat liver and kidney immune inflammation reaction, the activation of the HMGB1 / TLR4 / NF-kappa B signal channel is inhibited through the intervention of the dimethyl fumarate, the Th1 / Th2 / Th17 / Treg balance disorder caused by the sodium arsenite and the CD4 + T cell subset differentiation disorder are antagonized, and the arsenic-induced rat liver and kidney immune inflammation reaction is alleviated; a rat subchronic arsenic exposure model is established, dimethyl fumarate is adopted for intervention, arsenic-induced liver and kidney tissue immune inflammatory response and CD4 + T cell subset differentiation disorder are discussed on the basis of an HMGB1 / TLR4 / NF-kappa B signal channel, and the antagonism and potential action mechanism of dimethyl fumarate in arsenic-induced rat immune injury are preliminarily clarified. And a theoretical basis and a research thought are provided for arsenic poisoning prevention and treatment.

The invention discloses an establishment method and application of a rat acute inflammation model for simulating clinical inflammation, and relates to the technical field of biology. According to the invention, lipopolysaccharide is taken as a modeling drug, continuous intraperitoneal injection is carried out on a rat at the dosage of 20-40 [mu] g / kg, 30-50 [mu] g / kg and 40-60 [mu] g / kg for three days, and expression and release of interleukin-6 are promoted by activating a Toll-like receptor 4 signal channel, so that the acute inflammation model of the rat is established. The established rat acute inflammation model can cause significant increase of inflammatory biomarkers such as interleukin-6, C-reactive protein and alpha1 acid glycoprotein on the basis of not causing rat liver and kidney injury, and is more similar to clinical acute inflammation states; and a new experimental animal model is provided for exploring the influence of acute inflammation on pharmacokinetics of drugs.

The invention relates to the technical field of image data processing, in particular to a fatty liver lesion image analysis method based on color texture features, which comprises the following steps: extracting a rat liver region through image segmentation, and converting the rat liver region into a CIELAB color space to separate brightness, red-green degree and yellow-blue degree components; calculating a local texture difference feature based on a pixel space neighborhood, and coupling a brightness value to construct a pixel-level validity weight to suppress specular reflection; and weighting and updating a K-Means clustering center by using a pixel-level validity weight, distinguishing a fatty degeneration region from a non-lesion region, and counting the number of pixel points to realize analysis of the fatty liver lesion image. The optical noise interference is accurately inhibited, the clustering accuracy is improved, the fatty liver lesion analysis accuracy is improved, and reliable technical support is provided for drug curative effect evaluation and pathological mechanism research.

The present invention relates to the technical field of traditional Chinese medicine, and in particular to the use of a composition in the preparation of a drug for treating metabolic-related fatty liver disease. The composition includes: coptis root, pinellia tuber, tuckahoe, immature bitter orange, safflower, lotus seed heart, sophora flavescens, cyperus rotundus, ginseng, ophiopogon japonicus and liquorice. The composition of the present invention is used to reduce the weight gain and liver index of rats with metabolic-related fatty liver disease, reduce the damage of metabolic-related fatty liver disease to rat liver, reduce the expression levels of TG, TC, LDL-C, ALT and AST in serum of metabolic-related fatty liver disease, increase the expression of HDL-C in serum, significantly upregulate the expression of PPARα, ACOX1, CPT-1, and LCAD mRNA in liver tissue, regulate the expression of key enzymes in the β-oxidation pathway of long-chain fatty acids, promote β-oxidation of long-chain fatty acids, reduce fat accumulation and the accumulation of triglycerides, thereby delaying liver fatty degeneration, inhibiting liver fat deposition, and playing a role in liver protection, and can be used for the treatment of metabolic-related fatty liver disease.

The application discloses a kind of near-infrared fluorescent probe for detecting GSH and its preparation method and biological imaging application, belong to biological analysis technical field, the fluorescent probe NRh-BZ is by being decorated to oxygen heterocyclic skeleton with hemicyanine, increase conjugated structure, realize the detection of GSH in near-infrared light region, belong to off-on type fluorescent probe, with high selectivity, sensitivity and low cytotoxicity, its emission wavelength is 746nm, detection limit is as low as 46.8nM, can be applied to the detection imaging of GSH in living cell MCF-7 and rat liver tissue, and tissue penetration depth reaches 150 μm.The fluorescent probe NRh-BZ prepared in the application can quantitatively detect GSH in various biological systems.

The invention relates to the technical field of animal model construction and evaluation, in particular to an evaluation method of a CCl4-induced cirrhosis model and application of the evaluation method. Comprising the following steps: S1, establishing a rat liver cirrhosis model by adopting a CCl4 induction mode; s2, performing ultrasonic imaging on the liver cirrhosis model rat to obtain a gray value of the liver of the liver cirrhosis model rat; s3, evaluating the liver injury degree of the liver cirrhosis model rat according to the gray value of the liver of the liver cirrhosis model rat. The invention provides a method for accurately and comprehensively evaluating the liver injury degree without preparing pathological tissue slices or detecting liver functions or additionally adding experimental animals, and the method has important significance on screening of animal models and development of related animal experiments.

The present application relates to the technical field of image data processing, and more particularly, to a fat liver lesion image analysis method based on color texture features, comprising: extracting a rat liver region through image segmentation, converting to a CIELAB color space to separate luminance, red-green chroma and yellow-blue chroma components; calculating local texture difference features based on a pixel space neighborhood, coupling luminance values to construct pixel-level effectiveness weights to suppress specular reflection; using pixel-level effectiveness weights to update K-Means clustering centers, distinguishing between steatosis regions and non-lesion regions, and counting pixel points to realize analysis of fat liver lesion images. The present application accurately suppresses optical noise interference, improves clustering accuracy, and improves fat liver lesion analysis accuracy, providing reliable technical support for drug efficacy evaluation and pathological mechanism research.

The invention relates to a tissue exosome extraction method, and belongs to the technical field of exosome extraction.The tissue exosome extraction method comprises the steps that calcium ions or magnesium ions are chelated through ethylene diamine tetraacetic acid, most adhesion factors lose effect, tissue cells are dispersed, and therefore exosomes in an extracellular matrix are released; and then separating the exosome in the liver tissue of the rat by adopting a differential ultracentrifugation method. Proteomics results show that the types of proteins extracted by the EDTA-2Na chelating method are more, meanwhile, more exosome proteins can be obtained, and the purity of the rat liver tissue exosome extracted by the EDTA-2Na chelating method is relatively high. And the EDTA-2Na chelating method is simple and easy to implement and stable in effect, the operation at 4 DEG C can better maintain the activity of the exosome compared with the operation at 37 DEG C in a collagenase method, and the EDTA-2Na raw material is wide in source and convenient to store.

The invention provides a traditional Chinese medicine composition for preventing and treating chronic and acute hepatic failure and application thereof. According to the important composition disclosed by the invention, aiming at the pathogenesis characteristic that ACLF toxin stasis and body resistance deficiency are interweaved, the effects of cutting, reversing, strengthening the body resistance and expelling evil are achieved by combining cutting, twisting and countercurrent pulling. Animal model experiment results show that the traditional Chinese medicine composition has an obvious treatment effect on induced ACLF, can obviously reduce ACLF rat liver coefficient, improve liver and kidney functions, improve blood coagulation function, reduce blood ammonia and relieve liver injury, and has an improvement effect on liver injury and hepatic fibrosis symptoms caused by ACLF.

The invention provides a high-performance supramolecular hydrogel for hemostasis and wound closure and a preparation method thereof. The preparation method comprises the following steps: synthesizing a monomer 4-(6-(3-(6-methyl-4-oxy-1, 2, 4-triazole-4-yl)-1, 2, 4-triazole-4-yl)-1, 2, 4-triazole-4-yl)-1, 2, 4-triazole-4-yl)-1, 2, 4-triazole-4-yl)-1, 2, 4-triazole-4-yl)-1, 2, 4-triazole-4-yl)-1, 2, 4-triazole-4-yl the monomer is 2-(2, 4-dihydropyrimidine-2-yl) ureido) hexylcarbamoyloxy)-ethyl acrylate, the monomer is composed of an acrylic acid head, a hydrophobic alkyl spacer connected with carbamate and a self-complementary 2-2-ureido-4-pyrimidone motif, and hydrophobic association and quadruple hydrogen bonds are generated; under the condition that an emulsifier and a chemical cross-linking agent are not used, initiating monomer copolymerization through a photoinitiator, and introducing epigallocatechin gallate, so as to obtain the supramolecular hydrogel. The supramolecular hydrogel disclosed by the invention shows the properties of high strength, high toughness, high elasticity and the like, and shows excellent hemostasis and wound closure capabilities in rat liver puncture and incision models and full-thickness skin incision models.

The utility model discloses a blood vessel cannula for rat liver transplantation, which comprises a cylindrical cannula body, a through hole is arranged on the cannula body, one end of the cannula body is fixedly connected with a clamping handle, an annular binding groove is arranged on the outer wall of the cannula body, and the binding groove is positioned on one side far away from the clamping handle. According to the utility model, when a liver transplantation operation is carried out on a rat, an operator can use tweezers to clamp the clamping handle, clamp up the sleeve, then sleeve the tube body on one blood vessel and enable the blood vessel to pass through the through hole, and then turn one end of the blood vessel outwards and sleeve the outer wall of the tube body; finally, the other blood vessel is connected with the clamping handle in a sleeved mode and is bundled and fixed, the transplantation operation can be completed, in the operation process, tweezers clamp the clamping handle, the tube body can be made to be stable, the blood vessel can penetrate through the tube body more rapidly, and therefore the operation time is shortened, and the operation efficiency is improved.

The invention relates to a method for constructing a rat model for hepatic artery angiography and perfusion chemotherapy embolization through femoral artery, and relates to a novel hepatic artery angiography and perfusion chemotherapy embolization method which is established through research, in particular to a hepatic artery intubation angiography and chemotherapy embolization method for performing super selection through a rat femoral artery approach. The method is different from the traditional intubation angiography and chemoembolization which are retrograde from laparotomy to hepatic artery through stomach duodenal artery. According to the method, exposed wounds are obviously reduced, the infection incidence rate of the rats is reduced, the bleeding amount of the rats is reduced, and the success rate of an operation is increased. The injection of chemotherapy drugs and embolism particles on the liver tumor of the rat is carried out through the femoral artery path of the rat, so that the scientific research on the liver tumor of the rat through different treatment means is conveniently carried out and verified, the success rate of an operation is increased, related complications of the rat are reduced, and the requirements of large-scale related experimental research can be met.

The invention belongs to the technical field of traditional Chinese medicine fermentation, and particularly relates to a fermentation product for improving liver depression fire or liver aging and a preparation method thereof. The fermentation product is prepared from the following raw materials in parts by weight: 20 to 40 parts of fructus corni, 15 to 30 parts of fructus citri sarcodactylis, 10 to 25 parts of bolete, 10 to 20 parts of rhizoma nelumbinis, 6 to 16 parts of an enzyme preparation and 0.11 to 0.25 part of a leavening agent. The traditional Chinese medicine fermentation product provided by the invention is prepared from four raw materials, namely dogwood, fingered citron, bolete and rhizoma nelumbinis, the four raw materials are synergistically matched and synergistically act on the liver from multiple aspects, and animal experiments find that the traditional Chinese medicine fermentation product can improve the inflammatory factor level of a rat model with liver depression transforming into fire, can improve the liver aging index of a rat liver aging model, and can improve the liver aging index of the rat liver aging model. According to the invention, the purpose of treating liver aging or liver depression transforming into fire is achieved through a liver aging index, a liver injury biochemical index and an oxidative stress level index.

The present invention discloses the application of danshenolic acid in reducing the cytotoxicity of rat liver S9 cells. The present invention for the first time discovers that danshenolic acid has a strong protective effect on the cytotoxicity of the chemical mutagenicity test of rat liver S9 added with an in vitro activator, and does not affect the detection of mutagenicity. Danshenolic acid can be used as a protective agent for reducing the cytotoxicity of rat liver S9 cells; the present invention also provides a culture method for the mutagenicity test of reducing the cytotoxicity of rat liver S9 cells, which is economical and easily available; it is applicable to the mutagenicity test of adherent cells cultured in vitro in the safety evaluation of industrial chemicals, drugs and environmental chemicals.

The present invention provides a kind of Digeda-4 flavored composition for treating non-alcoholic fatty liver disease and its preparation method and application. The composition is made of raw materials: rib column flower, gardenia, superbus, picrorhizon, raw liquorice, turmeric powder, mulberry, rhubarb. The composition of the present invention can effectively reduce the weight of rats with non-alcoholic fatty liver disease model, reduce the content of TC, TG, AST, ALT in rat serum, reduce the content of MDA in rat liver, increase the content of SOD, and also increase the protein expression level of PPARα, PPARβ, LXRα in rat liver, and reduce the protein expression level of PPARγ, p-AKT, AKT; it has multi-component, multi-target, multi-channel effects, and can effectively prevent and treat the relevant symptoms of rats with non-alcoholic fatty liver disease model. The composition of the present invention is composed of a variety of raw materials, which can cooperate with each other, and this synergistic effect significantly enhances the therapeutic effect of non-alcoholic fatty liver disease.